X-linked premature ovarian failure: a complex disease

Current Opinion in Genetics and Development

Volumn 16, Issue 3, 2006, Pages 293-300

  Toniolo, Daniela ^a  

^a Department of Molecular Biology and Functional Genomics ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 15; FRAGILE X MENTAL RETARDATION PROTEIN; MESSENGER RNA;

APOPTOSIS; AUTOSOME; CHROMOSOME REARRANGEMENT; EVOLUTION; GENE FUNCTION; GENE LOCATION; GENE MAPPING; GENE MUTATION; GENETIC ORGANIZATION; HUMAN; MENTAL DEFICIENCY; OOCYTE DEVELOPMENT; OVARY FOLLICLE; OVARY FUNCTION; OVULATION; PARTIAL MONOSOMY; PHENOTYPE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; REVIEW; TURNER SYNDROME; X CHROMOSOME; X CHROMOSOME LINKED DISORDER;

ANIMALS; FEMALE; GENES, X-LINKED; HUMANS; MONOSOMY; MUTATION; OVARIAN FAILURE, PREMATURE; TURNER SYNDROME; X CHROMOSOME;

EID: 33646517073     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2006.04.005     Document Type: Review

References (82)

1. Coulam C.B., Adamson S.C., and Annegers J.F. Incidence of premature ovarian failure. Obstet Gynecol 67 (1986) 604-606
2. Goswami D., and Conway G. Premature ovarian failure. Hum Reprod Update 11 (2005) 391-410
3. Luborsky J.L., Meyer P., Sowers M.F., Gold E.B., and Santoro N. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod 18 (2003) 199-206
4. Moncayo R., and Moncayo H.E. Autoimmunity and the ovary. Immunol Today 13 (1992) 255-258
5. Luborsky J. Ovarian autoimmune disease and ovarian autoantibodies. J Womens Health Gend Based Med 11 (2002) 585-599
6. Aittomaki K., Lucena J.L., Pakarinen P., Sistonen P., Tapanainen J., Gromoll J., Kaskikari R., Sankila E.M., Lehvaslaiho H., Engel A.R., et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 82 (1995) 959-968
7. Di Pasquale E., Beck-Peccoz P., and Persani L. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet 75 (2004) 106-111. The authors provide the first demonstration of a mutation in the BMP15 gene associated with POF - in this case, the mutations were found in two sisters. The authors also report functional data showing that BMP15 has a role in human folliculogenesis.
8. Crisponi L., Deiana M., Loi A., Chiappe F., Uda M., Amati P., Bisceglia L., Zelante L., Nagaraja R., Porcu S., et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 27 (2001) 159-166
9. Fogli A., Rodriguez D., Eymard-Pierre E., Bouhour F., Labauge P., Meaney B.F., Zeesman S., Kaneski C.R., Schiffmann R., and Boespflug-Tanguy O. Ovarian failure related to eukaryotic initiation factor 2B mutations. Am J Hum Genet 72 (2003) 1544-1550
10. Laml T., Preyer O., Umek W., Hengstschlager M., and Hanzal H. Genetic disorders in premature ovarian failure. Hum Reprod Update 8 (2002) 483-491
11. Zinn A.R., and Ross J.L. Turner syndrome and haploinsufficiency. Curr Opin Genet Dev 8 (1998) 322-327
12. Rao E., Weiss B., Fukami M., Rump A., Niesler B., Mertz A., Muroya K., Binder G., Kirsch S., Winkelmann M., et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 16 (1997) 54-63
13. Belin V., Cusin V., Viot G., Girlich D., Toutain A., Moncla A., Vekemans M., Le Merrer M., Munnich A., and Cormier-Daire V. SHOX mutations in dyschondrosteosis (Leri-Weill syndrome). Nat Genet 19 (1998) 67-69
14. Shears D.J., Vassal H.J., Goodman F.R., Palmer R.W., Reardon W., Superti-Furga A., Scambler P.J., and Winter R.M. Mutation and deletion of the pseudoautosomal gene SHOX cause leri-weill dyschondrosteosis. Nat Genet 19 (1998) 70-73
15. Clement-Jones M., Schiller S., Rao E., Blaschke R.J., Zuniga A., Zeller R., Robson S.C., Binder G., Glass I., Strachan T., et al. The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome. Hum Mol Genet 9 (2000) 695-702
16. Blaschke RJ, Rappold G, The pseudoautosomal regions, SHOX and disease: Curr Opin Genet Dev 2006. 16: in press.
17. Speed R.M. The possible role of meiotic pairing anomalies in the atresia of human fetal oocytes. Hum Genet 78 (1988) 260-266
18. Ogata T., and Matsuo N. Turner syndrome and female sex chromosome aberrations: deduction of the principal factors involved in the development of clinical features. Hum Genet 95 (1995) 607-629
19. Simpson J.L., and Rajkovic A. Ovarian differentiation and gonadal failure. Am J Med Genet 89 (1999) 186-200
20. Zinn A.R., Tonk V.S., Chen Z., Flejter W.L., Gardner H.A., Guerra R., Kushner H., Schwartz S., Sybert V.P., Van Dyke D.L., et al. Evidence for a Turner syndrome locus or loci at Xp11.2-p22.1. Am J Hum Genet 63 (1998) 1757-1766
21. Ogata T., Muroya K., Matsuo N., Shinohara O., Yorifuji T., Nishi Y., Hasegawa Y., Horikawa R., and Tachibana K. Turner syndrome and Xp deletions: clinical and molecular studies in 47 patients. J Clin Endocrinol Metab 86 (2001) 5498-5508
22. Lachlan K.L., Youings S., Costa T., Jacobs P.A., and Thomas N.S. A clinical and molecular study of 26 females with Xp deletions with special emphasis on inherited deletions. Hum Genet 118 (2006) 640-651
23. Maraschio P., Tupler R., Barbierato L., Dainotti E., Larizza D., Bernardi F., Hoeller H., Garau A., and Tiepolo L. An analysis of Xq deletions. Hum Genet 97 (1996) 375-381
24. Marozzi A., Manfredini E., Tibiletti M.G., Furlan D., Villa N., Vegetti W., Crosignani P.G., Ginelli E., Meneveri R., and Dalpra L. Molecular definition of Xq common-deleted region in patients affected by premature ovarian failure. Hum Genet 107 (2000) 304-311
25. Cremers F.P., van de Pol D.J., Diergaarde P.J., Wieringa B., Nussbaum R.L., Schwartz M., and Ropers H.H. Physical fine mapping of the choroideremia locus using Xq21 deletions associated with complex syndromes. Genomics 4 (1989) 41-46
26. Krauss C.M., Turksoy R.N., Atkins L., McLaughlin C., Brown L.G., and Page D.C. Familial premature ovarian failure due to an interstitial deletion of the long arm of the X chromosome. N Engl J Med 317 (1987) 125-131
27. Rizzolio F., Bione S., Sala C., Goegan M., Gentile M., Gregato G., Rossi E., Pramparo T., Zuffardi O., and Toniolo D. Chromosomal rearrangements in Xq and premature ovarian failure: mapping of 25 new cases and review of the literature. Hum Reprod (2006) 10.1093/humrep/dei495. The authors report on a comparative analysis of different kinds of rearrangements in Xq and demonstrate a functional distinction between a POF critical region in Xq21 (critical region I) and one in the other part of Xq (critical region II). They also suggest a novel role for the critical region I in POF, not involving X-linked genes.
28. Schwartz C., Fitch N., Phelan M.C., Richer C.L., and Stevenson R. Two sisters with a distal deletion at the Xq26/Xq27 interface: DNA studies indicate that the gene locus for factor IX is present. Hum Genet 76 (1987) 54-57
29. Trunca C., Therman E., and Rosenwaks Z. The phenotypic effects of small, distal Xq deletions. Hum Genet 68 (1984) 87-89
30. •].
31. •].
32. •] describe small deletions in Xq27-q28qter, each associated with POF and causing phenotypic variability. The authors also show that the severity of the POF phenotype depends on additional factors; identical deletions can cause different phenotypes.
33. Gartler S.M., Andina R., and Gant N. Ontogeny of X-chromosome inactivation in the female germ line. Exp Cell Res 91 (1975) 454-457
34. Therman E., and Susman B. The similarity of phenotypic effects caused by Xp and Xq deletions in the human female: a hypothesis. Hum Genet 85 (1990) 175-183
35. Therman E., Laxova R., and Susman B. The critical region on the human Xq. Hum Genet 85 (1990) 455-461
36. Schlessinger D., Herrera L., Crisponi L., Mumm S., Percesepe A., Pellegrini M., Pilia G., and Forabosco A. Genes and translocations involved in POF. Am J Med Genet 111 (2002) 328-333
37. Turner J.M., Mahadevaiah S.K., Fernandez-Capetillo O., Nussenzweig A., Xu X., Deng C.X., and Burgoyne P.S. Silencing of unsynapsed meiotic chromosomes in the mouse. Nat Genet 37 (2005) 41-47
38. Sala C., Arrigo G., Torri G., Martinazzi F., Riva P., Larizza L., Philippe C., Jonveaux P., Sloan F., Labella T., et al. Eleven X chromosome breakpoints associated with premature ovarian failure (POF) map to a 15-Mb YAC contig spanning Xq21. Genomics 40 (1997) 123-131
39. Mumm S., Herrera L., Waeltz P.W., Scardovi A., Nagaraja R., Esposito T., Schlessinger D., Rocchi M., and Forabosco A. X/autosomal translocations in the Xq critical region associated with premature ovarian failure fall within and outside genes. Genomics 76 (2001) 30-36
40. Prueitt R.L., Chen H., Barnes R.I., and Zinn A.R. Most X;autosome translocations associated with premature ovarian failure do not interrupt X-linked genes. Cytogenet Genome Res 97 (2002) 32-38
41. Bione S., Sala C., Manzini C., Arrigo G., Zuffardi O., Banfi S., Borsani G., Jonveaux P., Philippe C., Zuccotti M., et al. A human homologue of the Drosophila melanogaster diaphanous gene is disrupted in a patient with premature ovarian failure: evidence for conserved function in oogenesis and implications for human sterility. Am J Hum Genet 62 (1998) 533-541
42. Prueitt R.L., Ross J.L., and Zinn A.R. Physical mapping of nine Xq translocation breakpoints and identification of XPNPEP2 as a premature ovarian failure candidate gene. Cytogenet Cell Genet 89 (2000) 44-50
43. Bione S., Rizzolio F., Sala C., Ricotti R., Goegan M., Manzini M.C., Battaglia R., Marozzi A., Vegetti W., Dalpra L., et al. Mutation analysis of two candidate genes for premature ovarian failure, DACH2 and POF1B. Hum Reprod 19 (2004) 2759-2766
44. van Bokhoven H., Schwartz M., Andreasson S., van den Hurk J.A., Bogerd L., Jay M., Ruther K., Jay B., Pawlowitzki I.H., Sankila E.M., et al. Mutation spectrum in the CHM gene of Danish and Swedish choroideremia patients. Hum Mol Genet 3 (1994) 1047-1051
45. Kleinjan D.A., and van Heyningen V. Long-range control of gene expression: emerging mechanisms and disruption in disease. Am J Hum Genet 76 (2005) 8-32
46. Wallrath L.L., and Elgin S.C. Position effect variegation in Drosophila is associated with an altered chromatin structure. Genes Dev 9 (1995) 1263-1277
47. Schotta G., Ebert A., Krauss V., Fischer A., Hoffmann J., Rea S., Jenuwein T., Dorn R., and Reuter G. Central role of Drosophila SU(VAR)3-9 in histone H3-K9 methylation and heterochromatic gene silencing. EMBO J 21 (2002) 1121-1131
48. Kingsley D.M. The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 8 (1994) 133-146
49. Hogan B.L. Bmps: multifunctional regulators of mammalian embryonic development. Harvey Lect 92 (1996) 83-98
50. Drummond A.E. TGFβ signalling in the development of ovarian function. Cell Tissue Res 322 (2005) 107-115
51. Su Y.Q., Wu X., O'Brien M.J., Pendola F.L., Denegre J.N., Matzuk M.M., and Eppig J.J. Synergistic roles of BMP15 and GDF9 in the development and function of the oocyte-cumulus cell complex in mice: genetic evidence for an oocyte-granulosa cell regulatory loop. Dev Biol 276 (2004) 64-73
52. McNatty K.P., Juengel J.L., Reader K.L., Lun S., Myllymaa S., Lawrence S.B., Western A., Meerasahib M.F., Mottershead D.G., Groome N.P., et al. Bone morphogenetic protein 15 and growth differentiation factor 9 co-operate to regulate granulosa cell function in ruminants. Reproduction 129 (2005) 481-487
53. Galloway S.M., McNatty K.P., Cambridge L.M., Laitinen M.P., Juengel J.L., Jokiranta T.S., McLaren R.J., Luiro K., Dodds K.G., Montgomery G.W., et al. Mutations in an oocyte-derived growth factor gene (BMP15) cause increased ovulation rate and infertility in a dosage-sensitive manner. Nat Genet 25 (2000) 279-283
54. McNatty K.P., Smith P., Moore L.G., Reader K., Lun S., Hanrahan J.P., Groome N.P., Laitinen M., Ritvos O., and Juengel J.L. Oocyte-expressed genes affecting ovulation rate. Mol Cell Endocrinol 234 (2005) 57-66
55. Garber K, Smith KT, Reines D, Warren ST, Transcription, translation, and fragile X syndrome: Curr Opin Genet Dev 2006. 16: in press.
56. Verkerk A.J., Pieretti M., Sutcliffe J.S., Fu Y.H., Kuhl D.P., Pizzuti A., Reiner O., Richards S., Victoria M.F., Zhang F.P., et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65 (1991) 905-914
57. Oberle I., Rousseau F., Heitz D., Kretz C., Devys D., Hanauer A., Boue J., Bertheas M.F., and Mandel J.L. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 252 (1991) 1097-1102
58. Fu Y.H., Kuhl D.P., Pizzuti A., Pieretti M., Sutcliffe J.S., Richards S., Verkerk A.J., Holden J.J., Fenwick Jr. R.G., Warren S.T., et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67 (1991) 1047-1058
59. Nolin S.L., Brown W.T., Glicksman A., Houck Jr. G.E., Gargano A.D., Sullivan A., Biancalana V., Brondum-Nielsen K., Hjalgrim H., Holinski-Feder E., et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet 72 (2003) 454-464. The authors carry out an accurate epidemiological analysis of the size of the FMR1 premutation in POF patients.
60. Tassone F., Hagerman R.J., Taylor A.K., Gane L.W., Godfrey T.E., and Hagerman P.J. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 66 (2000) 6-15
61. Kenneson A., Zhang F., Hagedorn C.H., and Warren S.T. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet 10 (2001) 1449-1454
62. Tassone F., and Hagerman P.J. Expression of the FMR1 gene. Cytogenet Genome Res 100 (2003) 124-128
63. Feng Y., Zhang F., Lokey L.K., Chastain J.L., Lakkis L., Eberhart D., and Warren S.T. Translational suppression by trinucleotide repeat expansion at FMR1. Science 268 (1995) 731-734
64. Primerano B., Tassone F., Hagerman R.J., Hagerman P., Amaldi F., and Bagni C. Reduced FMR1 mRNA translation efficiency in fragile X patients with permutations. RNA 8 (2002) 1482-1488
65. Beilina A., Tassone F., Schwartz P.H., Sahota P., and Hagerman P.J. Redistribution of transcription start sites within the FMR1 promoter region with expansion of the downstream CGG-repeat element. Hum Mol Genet 13 (2004) 543-549
66. Hagerman P.J., and Hagerman R.J. The fragile-X premutation: a maturing perspective. Am J Hum Genet 74 (2004) 805-816
67. Cronister A., Hagerman R.J., Wittenberger M., and Amiri K. Mental impairment in cytogenetically positive fragile X females. Am J Med Genet 38 (1991) 503-504
68. Schwartz C.E., Dean J., Howard-Peebles P.N., Bugge M., Mikkelsen M., Tommerup N., Hull C., Hagerman R., Holden J.J., and Stevenson R.E. Obstetrical and gynecological complications in fragile X carriers: a multicenter study. Am J Med Genet 51 (1994) 400-402
69. Allingham-Hawkins D.J., Babul-Hirji R., Chitayat D., Holden J.J., Yang K.T., Lee C., Hudson R., Gorwill H., Nolin S.L., Glicksman A., et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study-preliminary data. Am J Med Genet 83 (1999) 322-325
70. Conway G.S., Payne N.N., Webb J., Murray A., and Jacobs P.A. Fragile X premutation screening in women with premature ovarian failure. Hum Reprod 13 (1998) 1184-1187
71. Bretherick K.L., Fluker M.R., and Robinson W.P. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet 117 (2005) 376-382
72. Bodega B., Bione S., Dalpra L., Toniolo D., Ornaghi F., Vegetti W., Ginelli E., and Marozzi A. Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. Hum Reprod (2005) 10.1093/humrep/dei432
73. Uzielli M.L., Guarducci S., Lapi E., Cecconi A., Ricci U., Ricotti G., Biondi C., Scarselli B., Vieri F., Scarnato P., et al. Premature ovarian failure (POF) and fragile X premutation females: from POF to to fragile X carrier identification, from fragile X carrier diagnosis to POF association data. Am J Med Genet 84 (1999) 300-303
74. Murray A., Ennis S., MacSwiney F., Webb J., and Morton N.E. Reproductive and menstrual history of females with fragile X expansions. Eur J Hum Genet 8 (2000) 247-252
75. Murray A. Premature ovarian failure and the FMR1 gene. Semin Reprod Med 18 (2000) 59-66
76. Murray A., Webb J., MacSwiney F., Shipley E.L., Morton N.E., and Conway G.S. Serum concentrations of follicle stimulating hormone may predict premature ovarian failure in FRAXA premutation women. Hum Reprod 14 (1999) 1217-1218
77. Hundscheid R.D., Braat D.D., Kiemeney L.A., Smits A.P., and Thomas C.M. Increased serum FSH in female fragile X premutation carriers with either regular menstrual cycles or on oral contraceptives. Hum Reprod 16 (2001) 457-462
78. Hundscheid R.D., Sistermans E.A., Thomas C.M., Braat D.D., Straatman H., Kiemeney L.A., Oostra B.A., and Smits A.P. Imprinting effect in premature ovarian failure confined to paternally inherited fragile X premutations. Am J Hum Genet 66 (2000) 413-418
79. •].
80. •] establish correlations between characteristics of the FMR1 premutation and the risk of POF. Both studies demonstrate a non-linear association between menopausal age and premutation size, suggesting that individuals with premutations between 80 and 100 CGG repeats are at greatest risk of developing POF; the authors also show that larger premutations are at lower risk and propose several mechanisms that might explain the results.
81. Ebralidze A., Wang Y., Petkova V., Ebralidse K., and Junghans R.P. RNA leaching of transcription factors disrupts transcription in myotonic dystrophy. Science 303 (2004) 383-387
82. Vegetti W., Grazia Tibiletti M., Testa G., de Lauretis Y., Alagna F., Castoldi E., Taborelli M., Motta T., Bolis P.F., Dalpra L., et al. Inheritance in idiopathic premature ovarian failure: analysis of 71 cases. Hum Reprod 13 (1998) 1796-1800